


To provide long term capital appreciation and income.
| Name | % Net Assets |
|---|---|
| Aviva Inv Absolute TAA Fund | 5.0% |
| BG Group | 3.0% |
| GlaxoSmithKline | 2.6% |
| European Investment Bank 4.75% 2012 | 1.9% |
| Vodafone Group | 1.5% |
| Astrazeneca | 1.4% |
| HSBC Holdings PLC (UK Reg) | 1.4% |
| KFW Int Finance 5.625% 7/12/2009 | 1.3% |
| 2¼% Treasury Gilt 2014 | 1.0% |
| US Treasury 1.75% 31/03/2014 | 1.0% |
| Key | % Net Assets |
|---|---|
| 5.0% | |
| 3.0% | |
| 2.6% | |
| 1.9% | |
| 87.5% |
| Date | n/a |
|---|---|
| Bid | 0.00 |
| Offer | 0.00 |
| Currency | n/a |
| Change | 0.00 |
| % | n/a |
| YTD change | 0.00 |
| YTD % | n/a |
| Fund Inception | 19/02/2001 |
|---|---|
| Fund Manager | Peter Michaelis |
| Minimum Investment | |
|---|---|
| Initial | 500 |
| Additional | n/a |
| Savings | 50 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.10 |
You are here: research